mRNA Vaccine for Resected Pancreatic Cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new mRNA vaccine (AK154) alone or with other immunotherapy drugs after successful pancreatic cancer surgery. It also looks at adding chemotherapy later. The goal is to see if this treatment can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had pancreatic cancer removed with clear or nearly clear surgical margins (R0 or R1).
- You must be well enough to be out of bed most of the day (ECOG 0 or 1).
- You must not have received any prior treatment for pancreatic cancer before this trial, such as chemotherapy or radiation.
- You must not have an active autoimmune disease or a history of acute pancreatitis.
- You must agree to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine combined with an immunotherapy drug (PD-1 inhibitor) to prevent pancreatic cancer from returning after surgery. It is for patients whose tumors have specific genetic features and who cannot have standard chemotherapy.
This trial tests a personalized mRNA vaccine made from your tumor’s unique genetic features. It is given after surgery to prevent the pancreatic cancer from coming back.
This trial tests a personalized mRNA vaccine made from your own tumor's unique markers (neoantigens). It is for people with advanced pancreatic cancer that has spread or come back, and who have had limited or no prior chemotherapy. The goal is to see if this vaccine can help the immune system fight the cancer.
This trial tests a personalized vaccine plus a drug that helps your immune system attack cancer cells (a PD-L1 blocker) in people who have just had surgery for pancreatic cancer. The goal is to see if the combination can prevent the cancer from coming back.
This trial tests a new tumor vaccine combined with a standard chemotherapy regimen (AG) for people with metastatic pancreatic cancer. It aims to see if the combination is safe and helps the immune system fight the cancer.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
Hear when a new Pancreas Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.